Multi-targeted anticancer drugs: design strategies and recent development (Record no. 18995)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | a |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20230321104451.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 230321b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 20207 |
| Author | Vaishnaw, Aayush |
| 245 ## - TITLE STATEMENT | |
| Title | Multi-targeted anticancer drugs: design strategies and recent development |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol.16(4), Oct-Dec |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | M P |
| Name of publisher, distributor, etc. | BRNSS Publication Hub. |
| Year | 2022 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 328-333p. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Mono-targeted drug medications are less effective in complex multifactorial disorders involving several biochemical pathways and various types of mutation, such as cardiovascular disease, cancer, diabetes, and neurodegenerative syndromes, due to treatment resistance and side effects. Multiple targets drug simultaneously acting on a variety of targets may have several advantages, including enhanced therapeutic effects, less risk of drug interactions complications, improved patient compliance, and more predictable pharmacokinetics and pharmacodynamics. The multi-targeted anticancer agents such as Sunitinib, Sorafenib, Vandetanib, Pazopanib, Axitinib, Rituximab, Trastuzumab, Raltitrexed, Methotrexate, and Pemetrexed, are in clinically used and huge number are under different stages of clinical trials. The muti-targeted drug design strategies can be divided into three various steps: First is the selection of a target combination; the second is identifying the pharmacophore against individual targets; the last step is combining the identified pharmacophore for the development of the multi-targeted drug. The aim of the present review is to elucidate the recent advances in multi-targeted anticancer drugs. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4639 |
| Topical term or geographic name entry element | PHARMACEUTICS |
| 773 0# - HOST ITEM ENTRY | |
| Title | International journal of green pharmacy |
| International Standard Serial Number | 0973-8258 |
| Place, publisher, and date of publication | Mandsaur B.R. Nahata Smriti Sansthan |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| URL | https://www.greenpharmacy.info/index.php/ijgp/article/view/3344 |
| Link text | Click here |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Permanent Location | Current Location | Shelving location | Date acquired | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| School of Pharmacy | School of Pharmacy | Archieval Section | 2023-03-21 | 2023-0445 | 2023-03-21 | 2023-03-21 | Articles Abstract Database |